Precision medicine for neurodevelopmental disorders

  

About

Neurolentech GmbH is an early-stage biotech startup and first spin-out company from IST Austria founded in late 2020.

Our vision: Neurolentech empowers drug development for patients with neurodevelopmental disorders.


Motivation


More than 2% of the population suffer from neurodevelopmental disorders like autism or epilepsy. The economic, social, and emotional burdens for patients, families, and society are enormous.


There are no cures and no medications to fight the causes or alleviate the symptoms.

Approach


Brain developmental disorders are genetically determined and show a huge variety in their causes and disease mechanisms. 

In order to address this complexity and to develop tools and data for precision development of disorder-specific drugs we are building a platform for the generation and analysis of brain cell models from individual patients. 


Stem cells induced from blood or skin cells are generated from each patient, which are then reprogrammed into brain cells that are genetically and functionally identical to the brain cells in the patient's head.

The patient-specific brain cells are precisely characterized by molecular and functional investigations.  

Data from individual patients and the corresponding disorder cell models will enable the development of new therapeutic approaches and suitable diagnostic tools.  

Team

Carsten Pfeffer, PhD

Carsten Pfeffer, PhD

Carsten Pfeffer, PhD

CEO and Co-Founder

Gaia Novarino, PhD

Carsten Pfeffer, PhD

Carsten Pfeffer, PhD

Co-Founder and Scientific Advisor

Christoph Bock, PhD

Carsten Pfeffer, PhD

Christoph Bock, PhD

Co-Founder and Scientific Advisor

Eva Reinthaler, PhD

Federico Salaris, PhD

Eva Reinthaler, PhD

Research Scientist

Karin Stecher, PhD

Federico Salaris, PhD

Eva Reinthaler, PhD

Research Scientist

Federico Salaris, PhD

Federico Salaris, PhD

Federico Salaris, PhD

Research Scientist

Camilla Bosone, PhD

Federico Salaris, PhD

Federico Salaris, PhD

Research Scientist

Melanie Pieraks, MSc

Maria Fraga Pires, MSc

Martina Servetti, MSc

Research Specialist

Lab Manager

Martina Servetti, MSc

Maria Fraga Pires, MSc

Martina Servetti, MSc

Research Specialist

Maria Fraga Pires, MSc

Maria Fraga Pires, MSc

Maria Fraga Pires, MSc

Research Specialist

Funding

IST CUBE

In 2021 Neurolentech receives seed investment from IST CUBE

MORE

USP7

In 2021 the foundation for USP7 related diseases announces grant to Neurolentech

MORE

TESS

In 2021 TESS foundation announces grant to Neurolentech

MORE

News and More

IST Techtober 2020

Riz up genius award 2020

Riz up genius award 2020

Short Video about Neurolentech

MORE

Riz up genius award 2020

Riz up genius award 2020

Riz up genius award 2020

Ideen und Gründer Preis for Neurolentech

MORE

Partners

Contact us

Diese Website ist durch reCAPTCHA sowie die Datenschutzbestimmungen und Nutzungsbedingungen von Google geschützt.

Please contact us if you would like to learn more.

  


-Neurolentech GMBH, IST Science Park, Ploecking 1, 3400 Klosterneuburg Austria-

Copyright © 2021 Neurolentech – Alle Rechte vorbehalten.

Unterstützt von GoDaddy

  • Datenschutzerklärung
  • Impressum / Kontakt